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Approximately 40% of patients affected by core binding factor (CBF) acute myeloid leukemia (AML)
ultimately die from the disease. Few prognostic markers have been identified. We reviewed 192 patients with
CBF AML, treated with curative intent (age, 15–79 years) in 11 Italian institutions. Overall, 10-year overall
survival (OS), disease-free survival (DFS), and event-free survival were 63.9%, 54.8%, and 49.9%, respectively;
patients with the t(8;21) and inv(16) chromosomal rearrangements exhibited significant differences at
diagnosis. Despite similar high complete remission (CR) rate, patients with inv(16) experienced superior DFS
and a high chance of achieving a second CR, often leading to prolonged OS also after relapse. We found
that a complex karyotype (i.e., 4 cytogenetic anomalies) affected survival, even if only in univariate
analysis; the KIT D816 mutation predicted worse prognosis, but only in patients with the t(8;21)
rearrangement, whereas FLT3 mutations had no prognostic impact. We then observed increasingly better
survival with more intense first-line therapy, in some high-risk patients including autologous or allogeneic
hematopoietic stem cell transplantation. In multivariate analysis, age, severe thrombocytopenia, elevated
lactate dehydrogenase levels, and failure to achieve CR after induction independently predicted longer OS,
whereas complex karyotype predicted shorter OS only in univariate analysis. The achievement of minimal
residual disease negativity predicted better OS and DFS. Long-term survival was observed also in a minority
of elderly patients who received intensive consolidation. All considered, we identified among CBF AML
patients a subgroup with poorer prognosis who might benefit from more intense first-line treatment.
Am. J. Hematol. 90:515–523, 2015. VC 2015 Wiley Periodicals, Inc.
 Introduction
Core binding factor (CBF) acute myeloid leukemia (AML), defined by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22) [1]
represents approximately 15% of all AML in younger patients, and 7% in patients older than age 60 years [2–5]. It is debated whether t(8;21) and
inv(16) should be considered distinct entities [6–9]. Despite the common finding of additional cytogenetic abnormalities, such as loss of a sex
chromosome and/or deletions of chromosome 9q for t(8;21) [2,3,10], and trisomies of chromosomes 22, 8, and 21 for inv(16) [8–10], their role in
the pathogenesis and prognosis of CBF AML is still uncertain [3,8,11].
This type of leukemia is usually considered “favorable” [3,12–14], when patients are treated with induction chemotherapy followed by multiple
cycles of high-dose cytarabine (HiDAC) [13,14]. Therefore, CBF AML patients are not considered candidates for allogeneic hematopoietic stem
cell transplantation (HSCT) in first complete remission (CR1) by the National Comprehensive Cancer Network (NCCN) [15] or the European
LeukemiaNet (ELN) [16]. However, relapse, in the order of 40–50%, remains the main cause of treatment failure [8,13]. Patients with the t(8;21)
translocation seem to have a worse disease-free survival (DFS) and overall survival (OS) than those with inv(16) [4,5,13]. Growing evidence of
genetic heterogeneity of CBF AML [13], e.g. involving tyrosine kinases, such as KIT, FLT3, and RAS, could partly explain such disparity
[11,17–20]. In particular, the KIT D816 mutation has been associated with unfavorable DFS and OS, mostly in the case of t(8;21) patients [11].
Despite recent studies [21–24] proving its prognostic value in CBF AML patients, the use of minimal residual disease (MRD) monitoring by quan-
titative RT-PCR to determine clinical decisions for patients at high risk of relapse is still mainly limited to ongoing trials [21,23,24]. Consequently,
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until MRD monitoring overcomes its present issues regarding stand-
ardization and wide-spread availability, up-front risk stratification
based on clinical and biological markers remains a useful tool to
refine clinical decisions.
In this study, we retrospectively evaluated a large series of patients
with CBF AML diagnosed and treated at 11 different Italian hematol-
ogy institutions in the last two decades.
 Methods
Patients. We retrospectively reviewed 192 patients treated with curative intent
in 11 Italian hematology institutions from 1987 to 2012. Minimal required follow-
up was 6 months. Consent to use the medical records was obtained from all
patients according to the existing regulations at diagnosis.
In eight patients, the diagnosis of AML followed a previous cancer treated with
either chemotherapy or radiotherapy (four non-Hodgkin lymphomas, two Hodgkin
lymphomas, one colon cancer, and one breast cancer); in two more patients, a pre-
vious history of myelodysplastic syndrome lasting >6 months was present; and in
one patient, AML emerged in the context of chronic myeloid leukemia from a
Philadelphia-negative clone.
We defined “granulocytic sarcoma” as a mass-forming extramedullary localiza-
tion of AML with histological confirmation; when extramedullary localization was
suspected based on imaging but without measurable masses or histological confir-
mation, we named it “extramedullary disease.”
Laboratory, cytogenetic, and molecular data. All patients had clinical examina-
tion, complete laboratory profile, and morphologic and immunophenotypic charac-
terization of leukemic blasts evaluated at diagnosis.
Cytogenetics was performed at diagnosis according to the International System
for Human Cytogenetic Nomenclature [25]. Chromosome banding analysis was
performed on bone marrow cells after short-term culture (24–48 hr). A total of 20
metaphase cells were analyzed for each patient, and subclone analysis was provided
when different pathologic clones coexisted, or the CBF AML clone was present
together with cytogenetically normal hematopoiesis.
Molecular analysis in most recent years included data for mutations in KIT
(n5 59; 30.7%) [11], FLT3 (n5 101; 52.6%) [26], and NPM1 (n5 79; 41.1%) [27],
as per previously described methods. MRD analysis for RUNX1/RUNX1T1 and
CBFB/MYH11 at regular time points (end of induction, end of consolidation, post-
HSCT) was performed on 60 patients as per previously described methods [28,29],
with a cutoff of transcript level to define MRD-negativity of 12 copies after normal-
ization to 104 copies of ABL.
Chemotherapy. Induction regimens in patients aged 18–60 years were catego-
rized into: (1) D3A7 regimen, consisting of Daunorubicin 45 mg/m2 days 1–
31 intravenous cytarabine continuous infusion 100 mg/m2 days 1–7 or other simi-
lar 2-drug regimens consisting of an anthracycline plus standard-dose cytarabine;
(2) similar 2-drug regimens with intermediate-dose cytarabine (IDAC; 1–1.5 g/m2
bid days 1–4) or HiDAC (3 g/m2 bid days 1–4) plus an anthracycline (e.g., HAM,
HiDAC1 idarubicin); (3) 3-drug regimens, adding etoposide 50 mg/m2 days 1–5
or other drugs (e.g., thioguanine 200 mg/m2 days 1–5 in the ETI and days 1–7 in
the AAT regimens), excluding purine nucleoside analogues to anthracycline and
cytarabine (e.g., ICE, MICE, DAV/DAE/DCE, MEC, BARTS, ETI, AAT); (4) 3-
drug fludarabine-based regimens, with fludarabine 25–30 mg/m2 days 1–5 or, in a
few cases, other purine analogues as the third drug together with cytarabine 1–2 g/
m2 qid days 1–5 and an anthracycline (e.g., FLAI5, FLAIRG, FLAN, FLAIE); (5) 3-
drug fludarabine-based similar regimens with the addition of anti-CD33 Gemtuzu-
mab Ozogamicin (e.g., My-FLAI).
Following induction, patients achieving CR1 were consolidated with 1 IDAC/
HiDAC-based consolidation courses (median: two cycles; range, 1–4; median dose
of cytarabine given overall in consolidation: 24 g/m2; range, 6–94). After 2–3
courses, autologous HSCT (ASCT) was implemented in (1) patients considered at
high risk of relapse because of adverse clinical or laboratory findings at diagnosis
(e.g., hyperleukocytosis, i.e., >105/mm3 white blood cells [WBC]; secondary CBF
AML; extensive bone marrow, hepatic, and splenic infiltration; granulocytic sar-
coma); (2) patients failing to achieve CR1; (3) patients who achieved hematologic
but not cytogenetic CR1 after induction therapy; (4) patients with persisting or later
relapsing molecular transcripts. A small group of patients with available HLA-
matched donors (n5 29) was treated with allogeneic HSCT at the end of first-line
treatment for the same reasons. BuCy, BuMel, BAVC, fTBI1CTX,
fTBI1CTX1ATG, and Flu-CTX were used as conditioning regimens for both
autologous or allogeneic HSCT, with BuCy as the most common regimen (62%).
All first-line allogeneic HSCT but 1 was performed after myeloablative
conditioning.
In relapsing patients, rescue therapy mainly included 3-drug fludarabine-based
regimens, and responding patients were consolidated whenever possible. After that,
second-line allogeneic HSCT was the treatment of choice in all patients with a
potential HLA-matched donor.
Patients aged >60 years were still intensively treated with curative intent, using
either the same regimen as younger patients or their reduced versions, when avail-
able in the literature.
Statistics. To test the differences in proportions, the Fisher exact and Pearson
v2 tests were used. The Mann–Whitney and two-way Student t tests were used to
compare nonparametric/parametric variables between two groups, whereas the
Kruskal–Wallis, 1-way ANOVA, and Holm-Sidak tests were used for multiple
groups. The Shapiro–Wilk test was preferred to test normal distribution. Differen-
ces were considered statistically significant for P 0.05.
As per February 2014, 134 patients (69.8%) were alive, with a median follow-up
of 73.4 months (6–294). OS was defined as the time from diagnosis to death from
all causes, or last follow-up. DFS was defined only in patients achieving CR1 as the
time from assessment of CR1 until relapse of leukemia, death from all causes, or
last follow-up. Event-free survival (EFS) was defined as the time from diagnosis to
any adverse event, including death from all causes, relapse, and treatment-related
death. With a competing risk survival approach, relapse mortality (RM) was
defined as death due to leukemia relapse, and non-relapse mortality (NRM) was
defined as death from any cause in the absence of leukemia. We used a Mantel-
Byar approach, treating allogeneic HSCT as a time-varying covariate, to test the
effects of allogeneic HSCT.
Survival curves were calculated according to the method by Kaplan–Meier, and
differences were tested using the log-rank test. We then applied Cox proportional
hazard modeling to evaluate potential prognostic factors on OS. Multivariate analy-
sis was carried out for those factors resulting in significant differences (i.e.,
P 0.05). KIT evaluation (n5 59) and MRD evaluation (n5 60) were excluded
TABLE I. Patient Characteristics
All (n 5 192) AML t(8;21) (n 5 80) AML inv(16) (n 5 112) P
Age, median (range), years 44 (15–79) 41.8 (15–79) 45.1 (15–73) 0.13
Patients >60 years, n (%) 26 (13.5) 9 (11.3) 17 (15.2) 0.43
Male:female ratio 1.37 1.16 1.55 0.34
AML type, n (%)
De novo 181 (94.3) 73 (91.3) 108 (96.4) 0.21
Secondary 11 (5.7) 7 (8.7) 4 (3.6) 0.21
Splenomegaly, n (%) 30 (15.6) 6 (7.5) 24 (21.4) 0.008
Hepatomegaly, n (%) 41 (21.4) 13 (16.3) 28 (25.0) 0.13
Lymphadenopathy, n (%) 35 (18.2) 7 (8.8) 28 (25.0) 0.005
Extramedullary disease, n (%) 15 (7.8) 3 (3.8) 12 (10.7) 0.10
Granulocytic sarcoma, n (%) 6 (3.1) 4 (5.0) 2 (1.8) 0.40
WBC (range), 3103/mm3 18.9 (1.2-656.0) 10.5 (1.2-289.4) 32.2 (1.7-656.0) <0.001
WBC 30 3 103/mm3, n (%) 67 (34.9) 11 (13.8) 56 (50.0) <0.001
WBC 100 3 103/mm3, n (%) 15 (7.8) 2 (2.5) 13 (11.6) 0.017
Platelets (range), 3103/mm3 38.0 (4.0-586.0) 31 (4-586) 41.5 (6-331) 0.04
Platelets 20 3 103/mm3, n (%) 50 (26.0) 27 (33.8) 23 (20.5) 0.016
Hemoglobin (range), g/dL 8.9 (3.1–15.0) 8 (3.4–13.6) 9.2 (3.1–15.0) 0.002
Packed marrow (>80%), n (%) 88 (45.8) 29 (36.3) 59 (52.7) 0.021
Elevated LDH, n (%) 138 (71.9) 53 (66.3) 85 (75.9) 0.62
AML, acute myeloid leukemia; LDH, lactate dehydrogenase; WBC, white blood cells.
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from the multivariate analysis because of incomplete data. To determine the effects
of the same factors on NRM and RM, we modeled survival analysis in a competing
risk setting, using death from different causes as mutually exclusive competing
events. Again, we considered allogeneic HSCT in this setting as a time-dependent
covariate. Cumulative incidence functions between groups were compared by the
Pepe–Mori test.
Statistical analyses were performed using Stata IC v.10.1 by StataCorp (College
Station, TX).
 Results
Patient characteristics
Patient characteristics are summarized in Table I. At diagnosis,
splenomegaly (24 vs. 6; P5 0.008) and lymphadenopathy (28 vs. 7;
P5 0.005) were more common with patients with inv(16) than
t(8;21). Patients with inv(16) AML had higher WBC (P< 0.001) and
lower platelet counts (P5 0.04), and a higher degree of bone marrow
substitution (P5 0.02). Hemoglobin level was lower in patients with
t(8;21) AML (P5 0.002). Eleven patients presented with secondary
CBF AML: their characteristics did not differ significantly (Supporting
Information Table 1).
Treatment and survival
Overall, OS of our series was 67.0% at 5 years and 63.9% at 10
years; 5-year and 10-year DFS were 58.2% and 54.8%, and 5-year and
10-year EFS were 53.9% and 49.9%, respectively. We observed a bet-
ter DFS rate for patients with inv(16) compared with t(8;21)
(P5 0.04; Fig. 1).
Over the years, 25 patients were treated with the D3A7 regimen
and 167 with more intensive regimens (IDAC/HiDAC based, n5 12;
3-drug regimens, n5 112; fludarabine based, n5 43) (Supporting
Information Table 2). There was no temporal bias toward the D3A7
regimen in the first decade covered by our study compared with the
more recent one (data not shown). We observed a more favorable
EFS after 3-drug or fludarabine-based regimens than after D3A7
(Supporting Information Fig. 1) (P5 0.043).
Both t(8;21) and inv(16) AML presented high CR1 rates (92.5% vs.
93.8%), with 29 of 74 patients (39.2%) relapsing in the case of t(8;21)
and 31 of 105 patients (29.5%) for inv(16). Median DFS was 62
months vs. unreached (at 74.6 months of follow-up) for t(8;21) and
inv(16) patients, respectively (P5 0.04). Age did not impact CR1
rates: by applying the age cutoff of 60 years at diagnosis, 23 elderly
patients achieved CR1 (88.5%) vs. 156 younger patients (95.1%;
P5 0.18). We observed an overall treatment-related mortality of four
patients (2.1%). Eleven patients not achieving CR1 experienced poor
survival, with a median OS of 2.2 months. We could not find any
correlation between clinical, laboratory, cytogenetic, or molecular fea-
tures and the chance to achieve CR1.
We then divided patients achieving CR1 according to the intensity
of consolidation therapy in four groups: (1) patients treated with 1–2
consolidation courses (n5 60 [33.5%]); (2) 3 intensive consolidation
courses (n5 57 [31.8%]); (3) 2–3 consolidation courses1ASCT
(n5 33 [18.4%]); and (4) first-line allogeneic HSCT (n5 27 [15.1%])
(Fig. 2). Secondary CBF AML was a criterion for allogeneic HSCT; as
such, 7 of these 11 patients underwent allogeneic HSCT in CR1. We
recognized a distinctive trend toward better survival as the dose
intensity increased. Outcome significantly improved from 5-years
DFS and OS of 29.7% and 52.7%, respectively, to 61.8% and 73.0%
with more intensive therapy, to 71.3% and 80.3% with ASCT and
83.7% and 91.3% with allogeneic HSCT (P< 0.001 and P5 0.005,
respectively). We noted a significant difference in OS and DFS
between patients consolidated with 1–2 courses as compared to 3–4
courses (P5 0.025 and P5 0.002, respectively), ASCT (P5 0.009 and
P< 0.001) and allogeneic HSCT (P5 0.003 and P< 0.001). On the
opposite, differences in OS were nonsignificant between 3 and 4
courses and ASCT (P5 0.43) or allogeneic HSCT (P5 0.15), while
DFS was better for patients undergoing allogeneic HSCT as compared
to 3–4 chemotherapy courses (P5 0.011), but equally good for
patients undergoing ASCT or 3–4 courses (P5 0.17; Fig. 2).
Allogeneic HSCT was performed as part of first-line treatment in
27 patients achieving CR1 after induction therapy and in 2 who
achieved CR only after a second reinduction course. Twenty-two
more patients allotransplanted after relapse of leukemia are discussed
in a separate section; no patient of this study was transplanted twice.
The characteristics of patients allotransplanted during first-line treat-
ment are provided in Supporting Information Table 3. The only sig-
nificant difference in this group was the prevalence of secondary
AML, which can be explained by secondary AML being one of the
Figure 1. Survival of patients with t(8;21) and inv(16) AML. AML, acute mye-
loid leukemia; DFS, disease-free survival; EFS, event-free survival; OS, over-
all survival.
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criteria determining the choice of allogeneic HSCT. We observed a
very low mortality in this group, with 25 patients (86.2%) alive at
follow-up, one patient dying because of relapse of leukemia, and 3
because of extensive chronic Graft-vs-Host-Disease (GVHD) (n5 2)
or Cytomegalovirus (CMV) reactivation (n5 1). Applying a time-
dependent competing risk survival approach, we found that allogeneic
HSCT during first-line therapy deeply reduced RM (P< 0.001) with-
out significantly increasing NRM (P5 0.81), with 5-year OS at 88.5%
and 5-year DFS at 83.7% (Fig. 3).
After relapse, patients with inv(16) had a slightly better chance to
achieve a second CR (CR2), although not at the level of statistical sig-
nificance (n5 21 of 25 [84.0%] vs. n5 16 of 24 [66.7%], respectively;
P5 0.20), with similar final OS (P5 0.28; Fig. 1).
The CR1 rate was high also in elderly (i.e., >60 years at diagnosis)
patients (23/26 [88.4%]). Fourteen patients of this group (53.8%)
were consolidated by 1–2 courses and four patients by 3 courses
(15.3%), whereas four more patients (15.3%) received ASCT and one
reduced-induction conditioning allogeneic HSCT. Overall, elderly
patients were less likely to undergo intensive consolidation therapy
(i.e., >2 courses) than younger patients (P5 0.042; Supporting Infor-
mation Table 4). Long-term DFS was achieved only in the more
intensively treated cohort. Five-year DFS and OS ranged from 11.3%
and 20.2% for patients consolidated with 1–2 courses, to 62.2% and
62.2% in those treated more intensively (P5 0.002 and P5 0.019,
respectively). Notably, there were no treatment-related deaths among
these patients. When relapsing, elderly patients were less likely to
receive rescue therapy (P5 0.01; Supporting Information Table 4),
but, when treated, they had the same chance to achieve RC2
(P5 0.63). With the cutoff of 60 years, age proved one of the most
important predictors of poorer survival, with 5-year DFS and OS
dropping from 60.6% and 70.9% in younger patients to 34.5% and
35.6% in the elderly (P5 0.004 and P< 0.001; Supporting Informa-
tion Fig. 2).
Eleven patients (5.7%) presented with secondary CBF AML. They
all achieved CR1 (11/11, 100%), and experienced a similar relapse
rate as patients with de novo leukemia (4/11 vs. 56/167, P5 0.85). As
such, DFS and EFS did not differ (P5 0.224 and P5 0.581, respec-
tively). Seven of these patients underwent allogeneic HSCT in CR1,
while the remaining four received only chemotherapy because of the
lack of a HLA-matched donor (n5 2) or coexisting comorbidity
(n5 2). Eventually, OS of patients with secondary CBF AML
appeared slightly worse, with difference at the limit of statistical sig-
nificance (P5 0.049 at log-rank; P5 0.056 at Cox modeling).
Prognostic role of additional cytogenetic abnormalities
We detected additional cytogenetic abnormalities, listed in Table II
and in Supporting Information Table 5, in 83 patients (t[8;21] n5 42
[52.5%] and inv[16] n5 41 [36.6%; P5 0.18]).
We found a trend toward better OS and DFS for patients with
inv(16) and trisomy 22 and trisomy 8 (data not shown). As presented
in Fig. 4, only patients with 3 additional cytogenetic abnormalities
fared significantly worse than all other groups in terms of DFS
(P5 0.002) and EFS (P5 0.027; Fig. 4), and also in terms of OS with
Cox modeling (HR, 2.58; 95% CI, 1.02–6.49; P5 0.044; Table III).
This subgroup consisted of nine patients (4.7% of the whole), five
presenting with t(8;21) and four with inv(16); three patients were
aged >60 years and two presented with secondary AML. Eight
achieved CR following induction and four relapsed, with a median
DFS of 15.4 months. Three relapsing patients were treated with
second-line therapy, including allogeneic HSCT in two cases. The
presence of 3 additional cytogenetic abnormalities still identified (at
the limit of statistical significance) a subgroup with dismal prognosis
in t(8;21), but not inv(16) (HR, 2.85; 95% CI, .98–8.29; P5 0.055;
n5 5) (Supporting Information Tables 6 and 7).
Paradoxically, we observed a trend toward better survival in
patients with two additional cytogenetic abnormalities; in this group,
though, there were more patients with inv(16) as compared with the
others (19/31 [61.3%] vs. 18/43 [41.9%] and 4/9 [44.4%], respectively)
and frequent finding of trisomy 22 and trisomy 8 (45.2%), previously
associated with better OS in inv(16) patients [7].
We did not detect any prognostic role for the presence of
subclones.
Prognostic role of molecular data
Details are listed in Supporting Information Table 8. We observed
the presence of mutated FLT3 or NPM1 in rare cases (10/101 [9.9%]
and 2/79 [2.5%], respectively), whereas KIT was mutated in 7 of 59
patients (11.8%). KIT mutations predicted shorter OS at the univari-
ate analysis in patients with t(8;21) (HR, 12.5; 95% CI, 1.12–139.33;
P5 0.04) but not in patients with inv(16) (Table III). FLT3 mutations
did not predict worse OS or DFS, whereas NPM1 mutations could
not be analyzed (n5 2).
Molecular MRD
In patients where MRD was monitored (n5 60), we found a fun-
damental difference in survival between those achieving molecular CR
and those failing, regardless of the time point during treatment at
which MRD was negative (Supporting Information Fig. 3). Twenty-
three patients (38.3%) never achieved molecular remission and had a
median OS of 16.7 months (Supporting Information Fig. 3), despite
the use of ASCT and allogeneic HSCT in four and three patients,
respectively.
Figure 2. OS and DFS according to dose intensity of first-line treatment.
Allo-HSCT, allogeneic hematopoietic stem cell transplant; ASCT, autologous
hematopoietic stem cell transplant; DFS, disease-free survival; OS, overall
survival.
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Relapsing patients and second-line therapy
Overall, 60 patients (31.2%) relapsed, with similar rates in those
with t(8;21) and inv(16) AML (n5 29 [39.2%] vs. n5 31 [29.5%];
P5 0.19), resulting in only a slight advantage in DFS for patients
with inv(16) (P5 0.04; Fig. 1). When the intensity of treatment
given as first line was tested, we did not find any significant differ-
ence between patients relapsing with t(8;21) vs. inv(16) (data not
shown). In both groups, the chance of achieving CR2 after rescue
treatment was good (37/49 treated, 75.5%): 21/25 patients with
inv(16) achieved CR2 (84%) vs. 16/24 with t(8;21) (66.7%;
P5 0.20).
Twenty-two of the 37 relapsing patients achieving CR2 were then
consolidated by second-line allogeneic HSCT. Of these, four patients
later died of relapsing leukemia, six of infectious complications, and
one of chronic GVHD, leaving 11 patients (50%) alive at follow-up.
We found favorable relapse survival for the allotransplanted group
(P5 0.044; Supporting Information Fig. 4), because of a low RM
(P< 0.001), even if balanced by a higher NRM (P5 0.011; Supporting
Information Fig. 4).
Survival modeling
In the univariate analysis for OS (Table III), age (>60 years;
P< 0.001), severe thrombocytopenia (<20 3 103/mm3; P5 0.004),
increased LDH levels (P5 0.032), 3 additional cytogenetic abnor-
malities (P5 0.044), and failure to achieve CR1 (P< 0.001) identified
patients at higher risk. Of these, only age (P< 0.001), severe thrombo-
cytopenia (P5 0.027), increased LDH levels (P5 0.038), and failure to
achieve CR1 (P< 0.001) proved to be independent prognostic factors.
The diagnosis of secondary CBF AML only approached the level of
statistical significance (RR 2.30, CI 95%: 0.98–5.39, P5 0.056, Table
Figure 3. Survival according to first-line allogeneic HSCT. DFS, disease-free survival; HSCT, hematopoietic stem cell transplant; NRM, nonrelapse mortality;
OS, overall survival; RM, relapse mortality.
TABLE II. Additional Cytogenetic Abnormalities
All n = 192 (n =83 [43.2%]) t(8;21) n= 80 (n542 [52.5%]) inv(16) n = 112 (n541 [36.6%])
Single additional abnormality, n (%) 43 (22.4) 25 18
Trisomy 22 5 (2.6) – 5
Chromosome 7 2 (1.0) – 2
Chromosome 9 6 (3.1) 6 –
Trisomy 8 4 (2.1) 1 3
Chromosome 21 1 (0.5) – 1
Chromosomes X or Y 20 (10.4) 18 2
Mixed 5 (2.6) – 5
Two additional abnormalities, n (%) 31 (16.1) 12 19
Three (or more) additional abnormalities, n (%) 9 (4.7) 5 4
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III), and was therefore not considered in multivariate analysis. When
we analyzed OS for patients with t(8;21) or inv(16) AML separately
(Supporting Information Tables 6 and 7), we found that age, 3 addi-
tional cytogenetic abnormalities, and failure to achieve CR1 were inde-
pendent prognostic factors for patients with t(8;21), whereas only age
and severe thrombocytopenia remained independent prognostic fac-
tors in patients with inv(16). The KIT D816 mutation identified
patients with worse prognosis only in those with t(8;21) AML and
only in univariate analysis (Table III and Supporting Information
Table 6). Conversely, failure to achieve CR1 indicated adverse progno-
sis only in univariate, but not multivariate analysis for patients with
inv(16), thus highlighting the possibility to rescue failing patients with
second-line therapies (Table III and Supporting Information Table 7).
 Discussion
In our study, age proved to be a pivotal independent factor. Poor
survival in elderly AML patients usually reflects more aggressive dis-
ease, as well as the effect of comorbidities preventing the administra-
tion of an adequate treatment intensity [30]. Using a cutoff of 60
years, we observed a CR rate comparable for younger and older
patients, but a higher relapse rate and poorer OS in elderly patients.
These results are similar to what reported in a recent study [31], in
which a high induction-related toxicity prevented the administration
of consolidation therapy to most older patients [31]. In our cohort,
only one-third of elderly patients received intensive post-remission
therapy (data not shown). Nevertheless, long-term DFS and OS could
still be achieved in a significant proportion of these patients when
intensive consolidation was provided. We believe that this highlight
preserved chemosensitivity of CBF AML blasts also in elderly patients
[6,31].
Besides age, elevated LDH levels (P5 0.041) and low platelet count
at diagnosis (P5 0.016) proved to be independent predictors of
shorter OS, as in other studies [4,9,21,32].
We also tested whether the presence of high tumor burden (i.e.,
WBC count, bone marrow substitution, or hepatosplenic involve-
ment), might impact CR rate and survival. We found no correlation
between clinical and laboratory data and CR1 rate or final OS. This is
similar to what was reported by others [4,16], in which cytogenetic
and molecular data proved to be more powerful prognostic factors.
We therefore addressed the role of cytogenetics. In agreement with
most studies [4,8], we could not detect a prognostic value for single
additional abnormalities. The group defined by the presence of two
additional abnormalities showed a non-statistical advantage in sur-
vival, possibly because of the prevalence of patients with inv(16) in
this group, as well as by cytogenetic findings, such as trisomy 22 and
trisomy 21, already linked by others [8,17] to better prognosis.
Most significantly, though, we found that 3 additional cytoge-
netic abnormalities, herein defined as “complex karyotype,” predicted
significantly worse OS at univariate analysis. This was proved despite
the relative rarity of this subgroup. Effects were more evident for
patients with t(8;21) than those with inv(16). Differently from
another report [10], complex karyotype did not retain in our series
its prognostic value in multivariate analysis. So far, complex karyo-
type AML has been defined on a statistical basis as an indicator of
poor prognosis; its definition ranged from 3 to 5 independent
cytogenetic abnormalities in different clinical series [2,3,16]. A cutoff
of 3 independent abnormalities is commonly used to define com-
plex karyotype also in CBF AML [4,9,10]; as such, opposite to our
own results, most of these studies failed to detect a prognostic impact
of these on OS [4,9,21]. We believe this discrepancy to be possibly
explained by: (1) the lack of complete karyotypic data, also due to the
ever-growing use of molecular data as an alternative to cytogenetic
analysis; (2) the different definition of “complex karyotype” in CBF
AML that in our series, as in another one [3], required 4 independ-
ent cytogenetic abnormalities to identify patients with worse OS; (3)
the relative rarity of such patients. In our opinion, these patients
might deserve higher first-line intensity, possibly including ASCT. In
one study [33], ASCT after Busulfan-Etoposide-cytarabine condition-
ing managed to reverse molecular MRD-positivity in adverse risk
CBF AML patients, provided that the stem cell harvest was PCR-
negative for the molecular transcripts.
With the limitation of incomplete data, we also addressed the
prognostic role of KIT [11,17,18] FLT3 [20,34], and NPM1. The KIT
D816 mutation has been proposed to identify intermediate-risk CBF
AML [11,12,17,18]; these patients are also considered to have inter-
mediate risk by the ongoing cooperative GIMEMA AML1310 trial
and two studies by the NCI (ClinicalTrials.gov NCT01238211) and
Figure 4. Survival according to additional cytogenetic abnormalities. AML,
acute myeloid leukemia; DFS, disease-free survival; EFS, event-free sur-
vival; OS, overall survival.
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the German AMLSG (ClinicalTrials.gov NCT00850382) that both add
dasatinib to standard treatment. Mixed results have been obtained in
the patients with inv(16) AML [8,20,23]. In our series, the KIT muta-
tion predicted independent unfavorable OS for t(8;21) but not inv(16)
patients. NPM1 mutations proved mutually exclusive with CBF trans-
locations, as previously observed [20,35], whereas FLT3 mutations did
not seem to predict worse OS or EFS, similar to some studies [36]
and opposite to others [37]. It has been recently proposed that the
effect of FLT3 mutations on the prognosis of CBF AML depends on
the relative mutant level [20], which might explain these differences.
Besides cytogenetics, the overall dose-intensity of first-line treat-
ment proved to be pivotal in determining the final OS and DFS. We
observed a high CR rate with few deaths occurring during induction
also in the case of patients undergoing the more intensive induction
3-drug regimens. A study from the MDACC [38] reported similar
results comparing fludarabine-based regimens with more conventional
induction protocols. The most recently published results of the MRC
group on the FLAG1idarubicin regimen for younger patients, more-
over, improved historical results, especially in the “favorable” and
“intermediate-risk” categories [39]. However, in our series, the better
control over the disease obtained by more intensive induction ulti-
mately resulted only in a trend toward better OS, probably because of
the high probability of achieving CR2 with rescue therapy. Despite
this, failure to achieve CR after induction still translated into more
than six times higher relative risk of dying of disease (P< 0.001).
Repetitive HiDAC courses given as consolidation therapy are cur-
rently considered the standard primary treatment for CBF AML, even
if overall dose of cytarabine may vary [15,16]. A clear advantage in
terms of DFS has been demonstrated for HiDAC (i.e., 3 g/m2 bid at
days 1,3,5) compared with 400 mg/m2 and lower doses of cytarabine
[40] or as repetitive courses compared with 1 cycle only [4]. Despite
this, not all related studies eventually demonstrated a significant pro-
longation in OS [41], and the overall dose of cytarabine needed to
achieve best results is still uncertain [13,21,41]. In our series, intensive
first-line treatment, consisting of repetitive courses of HiDAC (3)
or ASCT performed after 2–3 HiDAC-based cycles, proved to be the
most important factor in determining final DFS and OS. We also
could not detect a linear relationship between the overall dose of
administered cytarabine and eventual survival [13,41]; in fact, when
excluding patients undergoing allogeneic HSCT during first-line treat-
ment, the best OS in our series was found in patients treated with
15–24 g/m2 of cytarabine overall (data not shown). As noted by
others [41], an administered dose of 6–12 g/m2 of cytarabine per
cycle should pharmakocynetically saturate the target of the drug and
provide the best results in terms of cytotoxicity. In fact, in our data
as in other studies [4,13,41], the number of repetitive IDAC/HiDAC
cycles seems more important than overall cytarabine dose in deter-
mining eventual survival: we observed a clear advantage between
patients consolidated with 3–4 courses as compared to 1–2 courses,
while the difference between 3–4 course and ASCT did not appear
significant. Furthermore, a minority of selected patients treated with
first-line allogeneic HSCT experienced a surprisingly good DFS and
OS, as a consequence of low RM and unexpectedly low NRM, prob-
ably due to patient selection. All of this considered, in line with what
reported by the CALGB group [4], and with the guidelines by the
NCCN [15] and the ELN [16], we believe that 3–4 courses of IDAC/
HiDAC should remain the standard consolidation treatment in CR1.
Alternatively, ASCT might be beneficial for selected patients present-
ing with features of aggressive disease [42]. Prospective randomized
trials would be needed to properly address this issue. The role of allo-
geneic HSCT for CBF AML patients in CR1 has been reviewed in a
meta-analysis that included 547 AML patients with favorable cytoge-
netics [43]: no advantage was found in neither relapse-free (RR 1.06,
95% CI, 0.80–1.42) nor overall survival (RR 1.07; 95% CI, 0.83–1.38)
[43]. Considering the retrospective non-randomized nature of our
own analysis, we also do not suggest the use of first-line allogeneic
HSCT, despite the good OS and DFS we observed in our series; com-
parable results can be achieved with less toxic approaches.
Overall intensity of first-line treatment might be rationally modu-
lated by the use of molecular MRD monitoring [23,24,44,45]. Several
studies have shown how the integration of MRD into clinical proto-
cols holds the potential to supersede the risk assessment made at
diagnosis [44,45]. At present, however, the use of MRD monitoring is
still limited by the lack of interlaboratory standardization and
TABLE III. Univariate and Multivariate Proportional Hazard Modeling for Potential Factors Impacting Overall Survival
Univariate analysis Multivariate analysis
RR (95% CI) P RR (95% CI) P
Age >60 years 3.05 (1.69–5.51) <0.001 4.52 (2.24–9.12) <0.001
Secondary AML 2.30 (0.98–5.39) 0.056
Male 0.98 (0.58–1.66) 0.95
Splenomegaly 1.02 (0.50–2.08) 0.96
Hepatomegaly 1.13 (0.62–2.07) 0.69
2 lymph nodes 0.41 (0.15–1.13) 0.084
Extramedullary disease 1.44 (0.68–3.04) 0.50
Granulocytic sarcoma 1.50 (0.47–4.80) 0.50
WBC 30 3 103/mm3 1.07 (0.62–1.84) 0.81
Platelets 20 3 103/mm3 2.24 (1.29–3.91) 0.004 1.99 (1.08–3.66) 0.027
Elevated LDH 3.60 (1.12–11.57) 0.032 3.52 (1.07–11.60) 0.038
DIC 0.70 (0.33–1.48) 0.35
inv(16) vs t(8;21) 0.75 (0.45–1.26) 0.28
3 additional cytogenetic abnormalities 2.58 (1.02–6.49) 0.044 1.47 (0.48–4.48) 0.50
Presence of subclones 1.15 (0.66–1.98) 0.63
Mutated KIT 2.33 (0.61–8.8) 0.21
Mutated FLT3 0.95 (0.28–3.17) 0.93
Packed marrow 1.37 (0.79–2.38) 0.26
Failure to achieve CR1 after induction therapy 6.21 (2.92–13.22) <0.001 5.43 (2.33–12.68) <0.001
The probability of dying while having the mentioned covariate (putative prognostic factor) is shown over the probability of dying while not having the covari-
ate (hazard ratio).
AML, acute myeloid leukemia; CR, complete remission; DIC, disseminated intravascular coagulation; FLT3, fms-like tyrosine kinase 3; LDH, lactate dehydro-
genase; RR, relative risk; WBC, white blood cells.
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inconsistencies in MRD thresholds and time points to use [44].
Besides, in the case of CBF AML very few prospective studies have
been published [23,24], with most information coming from the ret-
rospective analysis of limited numbers of patients [22]. Finally, the
reports of patients achieving long-term DFS while still with detectable
molecular transcripts [23,46] add further complexity to the clinical
translation of MRD monitoring; possible explanations of these find-
ings imply successful immune surveillance and/or the presence of
CBFB/MYH11 or RUNX1/RUNX1T1 in persisting pre-leukemic
clones. In this study, we detected a powerful advantage in survival for
patients achieving molecular MRD-negativity compared to patients
never achieving it. Nonetheless, we could not refine the precise time
points when the achievement of MRD-negativity proved most predic-
tive. Future ongoing trials will help to refine how MRD may be used
as a tool to drive clinical decisions.
The present series included 11 patients diagnosed with secondary
CBF AML: they did not differ in clinical and biological features as
compared to de novo leukemia. Similar to other reports [47,48], they
achieved CR1 at very high rate and experienced similar relapse rate;
this resulted in comparable DFS and EFS between the two groups.
Nevertheless, difference in OS almost approached statistical signifi-
cance; due to limited numbers, we could not assess whether this
reflected biological differences or the effect of comorbidity.
As postulated by others [4,13], we believe t(8;21) and inv(16) to be
distinct biological entities: in our series, they differed in clinical pre-
sentation, DFS, and response to second-line therapy. This difference,
in our opinion, becomes relevant especially in relapsing patients.
Although a high CR2 rate is achievable in both types of CBF AML,
in our series and in other studies [13,17], ultimate survival was signif-
icantly poorer with t(8;21). Recently, Kurosawa et al. [6] reported
that patients with t(8;21) acquired more commonly additional cytoge-
netic abnormalities at relapse and benefited more than inv(16)
patients from the use of second-line allogeneic HSCT [6].
In conclusion, we believe that our study contributes to the knowl-
edge about CBF AML by highlighting the presence of a small group
of patients, especially those with t(8;21), characterized by the presence
of 3 additional cytogenetic abnormalities, who ultimately have a
poor survival despite intensive chemotherapy. We also demonstrated
the importance of overall dose intensity of first-line treatment in
determining ultimate cure. Based on these results, we believe that
proper intensive consolidation, possibly including first-line ASCT
should be administered to all patients with CBF AML. Finally, a
recent study by the Surveillance, Epidemiology, and End Results
(SEER) demonstrated how survival in CBF AML patients sharply
declined in patients older than 65 years, possibly as a consequence of
undertreatment [5]. We, among others [31], found evidence indicat-
ing conserved chemosensitivity also in elderly (i.e., >60 years) CBF
AML patients; this, in our opinion, prompts the definition of more
precise criteria to exclude only truly unfit elderly patients from the
potential benefit deriving from chemotherapy.
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